

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$3.93
Change (%)	▲ 0.48 (13.91%)
Volume	313,095
52 Week Low	\$1.57
Market Cap	\$57,751,649
Rolling EPS	-1.54
PE Ratio	N/A
Shares Outstanding	14,695,076

Data as of 06/27/17 4:00 p.m. ET



Recent Headlines & Events

06/12/17 - 8:00 a.m.
Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma

06/08/17 - 8:01 a.m.
Fibrocell Completes Dosing of First Cohort in

There are currently no events scheduled.

Phase 1/2 Clinical Trial of FCX-007 Gene Therapy
for Treatment of Recessive Dystrophic
Epidermolysis Bullosa

05/17/17 - 8:00 a.m.

Fibrocell to Present at Inaugural Cell & Gene
Exchange 2017

SEC Filings

Filing Date	Form
06/27/17	8-K
06/26/17	4
06/26/17	4
06/26/17	4

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	41	16.10	54.7	8,042,750
Mutual Fund	18	2.78	9.0	1,318,713
Director and Officer	1	.25	0.7	105,600

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	5,540,140	37.7	2	03/31/17
Fidelity Management & Research Company	868,812	5.9	-1	03/31/17
MSD Partners, L.P.	692,960	4.7	1	03/31/17
The Vanguard Group, Inc.	394,266	2.7	3,181	03/31/17
Renaissance Technologies LLC	86,864	0.6	22,197	03/31/17
BlackRock Institutional Trust Company, N.A.	66,811	0.5	392	03/31/17
Geode Capital Management, L.L.C.	60,427	0.4	233	03/31/17
California Public Employees' Retirement System	36,333	0.3	0	03/31/17
Staley Capital Advisers, Inc.	32,834	0.2	1	03/31/17
Pernock (David)	32,699	0.2	-2,501	04/25/17

Data provided by Nasdaq. Minimum 15 minutes delayed.